Advice
Following an abbreviated submission
insulin glulisine (Apidra®) is accepted for restricted use within NHS Scotland for the treatment of adolescents and children, 6 years or older with diabetes mellitus, where treatment with insulin is required and for whom the use of a short-acting insulin analogue is appropriate.
Insulin glulisine has a similar efficacy to other short-acting insulins in reducing glycated haemoglobin and a similar pharmacokinetic profile to at least one other insulin analogue. It is restricted to use in patients where soluble human insulin is inappropriate.
The Scottish Medicines Consortium has previously accepted this product for restricted use for this indication in adults.
Download detailed advice31KB (PDF)
Medicine details
- Medicine name:
- Insulin glulisine (Apidra)
- SMC ID:
- 512/08
- Indication:
- For adolescents and children with diabetes mellitus
- Pharmaceutical company
- Sanofi-Aventis
- BNF chapter
- Endocrine system
- Submission type
- Abbreviated
- Status
- Restricted
- Date advice published
- 10 November 2008